Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

150 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin's lymphoma: final results of the GHSG HD7 trial.
Engert A, Franklin J, Eich HT, Brillant C, Sehlen S, Cartoni C, Herrmann R, Pfreundschuh M, Sieber M, Tesch H, Franke A, Koch P, de Wit M, Paulus U, Hasenclever D, Loeffler M, Müller RP, Müller-Hermelink HK, Dühmke E, Diehl V. Engert A, et al. Among authors: hasenclever d. J Clin Oncol. 2007 Aug 10;25(23):3495-502. doi: 10.1200/JCO.2006.07.0482. Epub 2007 Jul 2. J Clin Oncol. 2007. PMID: 17606976 Clinical Trial.
Rapidly alternating COPP/ABV/IMEP is not superior to conventional alternating COPP/ABVD in combination with extended-field radiotherapy in intermediate-stage Hodgkin's lymphoma: final results of the German Hodgkin's Lymphoma Study Group Trial HD5.
Sieber M, Tesch H, Pfistner B, Rueffer U, Lathan B, Brosteanu O, Paulus U, Koch T, Pfreundschuh M, Loeffler M, Engert A, Josting A, Wolf J, Hasenclever D, Franklin J, Duehmke E, Georgii A, Schalk KP, Kirchner H, Doelken G, Munker R, Koch P, Herrmann R, Greil R, Anselmo AP, Diehl V. Sieber M, et al. Among authors: hasenclever d. J Clin Oncol. 2002 Jan 15;20(2):476-84. doi: 10.1200/JCO.2002.20.2.476. J Clin Oncol. 2002. PMID: 11786577 Clinical Trial.
Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease.
Diehl V, Franklin J, Pfreundschuh M, Lathan B, Paulus U, Hasenclever D, Tesch H, Herrmann R, Dörken B, Müller-Hermelink HK, Dühmke E, Loeffler M; German Hodgkin's Lymphoma Study Group. Diehl V, et al. Among authors: hasenclever d. N Engl J Med. 2003 Jun 12;348(24):2386-95. doi: 10.1056/NEJMoa022473. N Engl J Med. 2003. PMID: 12802024 Free article. Clinical Trial.
Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin's lymphoma: results of the HD8 trial of the German Hodgkin's Lymphoma Study Group.
Engert A, Schiller P, Josting A, Herrmann R, Koch P, Sieber M, Boissevain F, De Wit M, Mezger J, Duhmke E, Willich N, Muller RP, Schmidt BF, Renner H, Muller-Hermelink HK, Pfistner B, Wolf J, Hasenclever D, Loffler M, Diehl V; German Hodgkin's Lymphoma Study Group. Engert A, et al. Among authors: hasenclever d. J Clin Oncol. 2003 Oct 1;21(19):3601-8. doi: 10.1200/JCO.2003.03.023. Epub 2003 Aug 11. J Clin Oncol. 2003. PMID: 12913100 Clinical Trial.
Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study.
Engert A, Diehl V, Franklin J, Lohri A, Dörken B, Ludwig WD, Koch P, Hänel M, Pfreundschuh M, Wilhelm M, Trümper L, Aulitzky WE, Bentz M, Rummel M, Sezer O, Müller-Hermelink HK, Hasenclever D, Löffler M. Engert A, et al. Among authors: hasenclever d. J Clin Oncol. 2009 Sep 20;27(27):4548-54. doi: 10.1200/JCO.2008.19.8820. Epub 2009 Aug 24. J Clin Oncol. 2009. PMID: 19704068 Clinical Trial.
Further chemotherapy versus low-dose involved-field radiotherapy as consolidation of complete remission after six cycles of alternating chemotherapy in patients with advance Hodgkin's disease. German Hodgkins' Study Group (GHSG).
Diehl V, Loeffler M, Pfreundschuh M, Ruehl U, Hasenclever D, Nisters-Backes H, Sieber M, Smith K, Tesch H, Geilen W, et al. Diehl V, et al. Among authors: hasenclever d. Ann Oncol. 1995 Nov;6(9):901-10. doi: 10.1093/oxfordjournals.annonc.a059357. Ann Oncol. 1995. PMID: 8624293 Free article. Clinical Trial.
Dose-response relationship of complementary radiotherapy following four cycles of combination chemotherapy in intermediate-stage Hodgkin's disease.
Loeffler M, Diehl V, Pfreundschuh M, Rühl U, Hasenclever D, Nisters-Backes H, Sieber M, Tesch H, Franklin J, Geilen W, Bartels H, Cartoni C, Dölken G, Enzian J, Fuchs R, Gassmann W, Gerhartz H, Hagen-Aukamp U, Hiller E, Hinkelbein H, Hinterberger W, Kirchner H, Koch P, Krüger B, Schwarze EW, et al. Loeffler M, et al. Among authors: hasenclever d. J Clin Oncol. 1997 Jun;15(6):2275-87. doi: 10.1200/JCO.1997.15.6.2275. J Clin Oncol. 1997. PMID: 9196141 Clinical Trial.
BEACOPP, a new dose-escalated and accelerated regimen, is at least as effective as COPP/ABVD in patients with advanced-stage Hodgkin's lymphoma: interim report from a trial of the German Hodgkin's Lymphoma Study Group.
Diehl V, Franklin J, Hasenclever D, Tesch H, Pfreundschuh M, Lathan B, Paulus U, Sieber M, Rueffer JU, Sextro M, Engert A, Wolf J, Hermann R, Holmer L, Stappert-Jahn U, Winnerlein-Trump E, Wulf G, Krause S, Glunz A, von Kalle K, Bischoff H, Haedicke C, Duehmke E, Georgii A, Loeffler M. Diehl V, et al. Among authors: hasenclever d. J Clin Oncol. 1998 Dec;16(12):3810-21. doi: 10.1200/JCO.1998.16.12.3810. J Clin Oncol. 1998. PMID: 9850026 Clinical Trial.
BEACOPP: a new regimen for advanced Hodgkin's disease. German Hodgkin's Lymphoma Study Group.
Diehl V, Franklin J, Hasenclever D, Tesch H, Pfreundschuh M, Lathan B, Paulus U, Sieber M, Rüffer JU, Sextro M, Engert A, Wolf J, Hermann R, Holmer L, Stappert-Jahn U, Winnerlein-Trump E, Wulf G, Krause S, Glunz A, von Kalle K, Bischoff H, Haedicke C, Dühmke E, Georgii A, Loeffler M. Diehl V, et al. Among authors: hasenclever d. Ann Oncol. 1998;9 Suppl 5:S67-71. doi: 10.1093/annonc/9.suppl_5.s67. Ann Oncol. 1998. PMID: 9926240 Review.
Low-dose radiation is sufficient for the noninvolved extended-field treatment in favorable early-stage Hodgkin's disease: long-term results of a randomized trial of radiotherapy alone.
Dühmke E, Franklin J, Pfreundschuh M, Sehlen S, Willich N, Rühl U, Müller RP, Lukas P, Atzinger A, Paulus U, Lathan B, Rüffer U, Sieber M, Wolf J, Engert A, Georgii A, Staar S, Herrmann R, Beykirch M, Kirchner H, Emminger A, Greil R, Fritsch E, Koch P, Drochtert A, Brosteanu O, Hasenclever D, Loeffler M, Diehl V. Dühmke E, et al. Among authors: hasenclever d. J Clin Oncol. 2001 Jun 1;19(11):2905-14. doi: 10.1200/JCO.2001.19.11.2905. J Clin Oncol. 2001. PMID: 11387364 Clinical Trial.
150 results